Apricus negotiates $20 million 'at the market' equity sales agreement

Ascendiant Capital assists with controlled equity offering agreement

By Devika Patel

Knoxville, Tenn., Dec. 30 - Apricus Biosciences, Inc. arranged a $20 million controlled equity offering agreement with Ascendiant Capital Markets, LLC on Dec. 30, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission.

The sales will be made in "at the market" offerings.

Apricus is a pharmaceutical research and development company based in East Windsor, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.